Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review

George V. Papatheodoridis, Pietro Lampertico, Spilios Manolakopoulos, Anna Lok

Research output: Contribution to journalArticle

Abstract

Background & Aims: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues. Methods: We performed a literature search to identify studies with chronic hepatitis B patients treated with nucleos(t)ide analogues for ≥24 months. Results: Twenty-one studies including 3881 treated and 534 untreated patients met our inclusion criteria. HCC was diagnosed in 2.8% and 6.4% of treated and untreated patients, respectively, during a 46 (32-108) month period (p = 0.003), in 10.8% and 0.5% of nucleos(t)ide naive patients with and without cirrhosis (p

Original languageEnglish
Pages (from-to)348-356
Number of pages9
JournalJournal of Hepatology
Volume53
Issue number2
DOIs
Publication statusPublished - Aug 2010

Keywords

  • Antivirals
  • Hepatitis B
  • Hepatocellular carcinoma
  • Lamivudine
  • Nucleoside analogues
  • Nucleotide analogues

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review'. Together they form a unique fingerprint.

  • Cite this